BACKGROUND: Interleukin-16 (IL-16) is a multifunctional cytokine which plays a key role in inflammatory and autoimmune diseases as well as in cancer. Genetic polymorphisms of IL-16 have been implicated in susceptibility to cancer. However, associations remain inconclusive. The present meta-analysis was therefore carried out to establish a more conclusive association of IL-16 polymorphisms with cancer risk. MATERIALS AND METHODS: Relevant studies were searched through the PubMed, Embase, Web of Science, Google Scholar and Wan fang electronic databases updated in October 2013. Odds ratios (OR) and 95% confidence intervals (95% CI) were used to assess the association between IL-16 polymorphisms and cancer risk. RESULTS: Eight eligible studies (rs4778889 T/C: 8, rs11556218 T/G: 7, rs4072111 C/T: 6) that met our selection criteria were included. The meta-analysis indicated that rs11556218 T/G was associated with a significant increased risk of cancer (G vs. T, OR=1.321, 95% CI=1.142-1.528, P <0.001; TG vs. TT, OR=1.665, 95% CI=1.448-1.915, P<0.001; GG+TG vs. TT, OR=1.622, 95% CI=1.416-1.858, P<0.001),as well as nasopharyngeal carcinoma and colorectal cancer. Furthermore, in the subgroup of Chinese, significant associations were found between rs11556218 polymorphism and cancer risk. There was no statistically significant association between the other two variants (rs4778889, rs4072111) and risk of cancer. CONCLUSIONS: This meta-analysis suggests that the IL-16 rs11556218 polymorphism is associated with increased cancer risk. Large well-designed studies involving various cancer types and different populations are now needed.
BACKGROUND:Interleukin-16 (IL-16) is a multifunctional cytokine which plays a key role in inflammatory and autoimmune diseases as well as in cancer. Genetic polymorphisms of IL-16 have been implicated in susceptibility to cancer. However, associations remain inconclusive. The present meta-analysis was therefore carried out to establish a more conclusive association of IL-16 polymorphisms with cancer risk. MATERIALS AND METHODS: Relevant studies were searched through the PubMed, Embase, Web of Science, Google Scholar and Wan fang electronic databases updated in October 2013. Odds ratios (OR) and 95% confidence intervals (95% CI) were used to assess the association between IL-16 polymorphisms and cancer risk. RESULTS: Eight eligible studies (rs4778889 T/C: 8, rs11556218 T/G: 7, rs4072111 C/T: 6) that met our selection criteria were included. The meta-analysis indicated that rs11556218 T/G was associated with a significant increased risk of cancer (G vs. T, OR=1.321, 95% CI=1.142-1.528, P <0.001; TG vs. TT, OR=1.665, 95% CI=1.448-1.915, P<0.001; GG+TG vs. TT, OR=1.622, 95% CI=1.416-1.858, P<0.001),as well as nasopharyngeal carcinoma and colorectal cancer. Furthermore, in the subgroup of Chinese, significant associations were found between rs11556218 polymorphism and cancer risk. There was no statistically significant association between the other two variants (rs4778889, rs4072111) and risk of cancer. CONCLUSIONS: This meta-analysis suggests that the IL-16rs11556218 polymorphism is associated with increased cancer risk. Large well-designed studies involving various cancer types and different populations are now needed.
Authors: Rachid Abaji; Vincent Gagné; Chang Jiang Xu; Jean-François Spinella; Francesco Ceppi; Caroline Laverdière; Jean-Marie Leclerc; Stephen E Sallan; Donna Neuberg; Jeffery L Kutok; Lewis B Silverman; Daniel Sinnett; Maja Krajinovic Journal: Oncotarget Date: 2017-07-04
Authors: Michail Matalliotakis; Maria I Zervou; Elias Eliopoulos; Charoula Matalliotaki; Nilufer Rahmioglu; Ioannis Kalogiannidis; Krina Zondervan; Demetrios A Spandidos; Ioannis Matalliotakis; George N Goulielmos Journal: Int J Mol Med Date: 2018-01-09 Impact factor: 4.101
Authors: Julia Y Ljubimova; Oliver Braubach; Rameshwar Patil; Antonella Chiechi; Jie Tang; Anna Galstyan; Ekaterina S Shatalova; Michael T Kleinman; Keith L Black; Eggehard Holler Journal: Sci Rep Date: 2018-04-09 Impact factor: 4.379
Authors: Victor Hugo de Souza; Josiane Bazzo de Alencar; Bruna Tiaki Tiyo; Hugo Vicentin Alves; Evelyn Castillo Lima Vendramini; Ana Maria Sell; Jeane Eliete Laguila Visentainer Journal: Oncotarget Date: 2020-09-08